Literature DB >> 16627966

Involvement of chemokine receptors in organ-specific metastasis.

Albert Zlotnik1.   

Abstract

The chemokines are a family of small proteins known for their ability to control cell migration in the body. Their receptors belong to the class A subfamily of G protein-coupled receptors. In recent years, chemokines have grown in importance, because they are involved in inflammation and autoimmune disease. Some of them are also involved in infectious disease, since two chemokine receptors, CXCR4 and CCR5, are used by the human immunodeficiency virus (HIV) to gain entry to cells. Several years ago it also became clear that chemokines can also influence tumor cells. Specifically, tumor cells express chemokine receptors in a nonrandom manner, and this suggested a role for chemokines in the metastatic destination of tumor cells. By far the most common chemokine receptor expressed by many cancer cells is CXCR4. Its ligand, CXCL12, is strongly expressed in lung, liver, bone marrow and lymph nodes, places that represent common metastatic destinations in many cancers. Many studies have now validated the concept that chemokines and their receptors influence metastasis. The potential therapeutic importance of these observations depends on the role that each metastatic destination such as liver, lung, bone marrow, etc., plays in the prognosis of a cancer patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627966     DOI: 10.1159/000092973

Source DB:  PubMed          Journal:  Contrib Microbiol        ISSN: 1420-9519


  55 in total

1.  Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression.

Authors:  Yu Zhi; Jing Chen; Shuanglong Zhang; Xiaojing Chang; Jingguo Ma; Dongqiu Dai
Journal:  Dig Dis Sci       Date:  2011-09-29       Impact factor: 3.199

Review 2.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

3.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

Review 4.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

Review 5.  Neuronal chemokines: versatile messengers in central nervous system cell interaction.

Authors:  A H de Haas; H R J van Weering; E K de Jong; H W G M Boddeke; K P H Biber
Journal:  Mol Neurobiol       Date:  2007-07-10       Impact factor: 5.590

Review 6.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

Review 7.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

8.  The CXCL12/CXCR4 autocrine loop increases the metastatic potential of non-small cell lung cancer in vitro.

Authors:  Xiaofeng Dai; Zhifu Mao; Jie Huang; Songping Xie; Hao Zhang
Journal:  Oncol Lett       Date:  2012-10-10       Impact factor: 2.967

Review 9.  Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner.

Authors:  Thomas Dittmar; Christoph Heyder; Eva Gloria-Maercker; Wolfgang Hatzmann; Kurt S Zänker
Journal:  Clin Exp Metastasis       Date:  2007-09-08       Impact factor: 5.150

10.  Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration.

Authors:  Tim Zimmermann; Markus Moehler; Ines Gockel; George G Sgourakis; Stefan Biesterfeld; Michaela Müller; Martin R Berger; Hauke Lang; Peter R Galle; Carl C Schimanski
Journal:  Int J Colorectal Dis       Date:  2010-04       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.